SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings Inc is trending after its CFO and General Counsel abruptly departed amidst an ongoing SEC accounting probe, invalidated financial disclosures, and significantly lowered guidance, triggering a massive stock sell-off. While many in the community express serious concerns about the company's financial integrity and long-term outlook, others view the steep decline as an overreaction and a potential opportunity for a bounce.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group is surging after announcing preliminary Q3 revenue that significantly exceeded prior guidance and analyst consensus, indicating robust demand for its AI infrastructure solutions. The community is highly bullish, anticipating sustained growth as the company plays a crucial role in the ongoing data center buildout.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health (OSCR) is trending sharply higher after the House passed a bill to extend ACA subsidies, fueling investor optimism for significant upside and a potential short squeeze, though community debate persists on the bill's Senate fate and the company's path to profitability ahead of its upcoming earnings.

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.

Satellos Bioscience Inc

Satellos Bioscience (MSLE) is trending after its NASDAQ debut was swiftly followed by a significant equity raise and reverse stock split, sparking a fierce debate among investors over immediate dilution versus the long-term funding for its potentially "revolutionary" muscle regeneration drug for Duchenne Muscular Dystrophy.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio Inc. is trending after the FDA issued a Complete Response Letter for its Hunter syndrome gene therapy, RGX-121, raising concerns about trial design and following a clinical hold on a related program due to a patient tumor; community discussion is split between fears of significant setbacks and a belief that other key pipeline assets, like the AbbVie partnership, still offer substantial value.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify (SPOT) is seeing heated debate leading into its Q4 earnings report, as bullish analysts and the rollout of new AI-powered features and price hikes contend with investor concerns over its valuation and a recent music catalog leak.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Advanced Micro Devices is experiencing a sharp rebound, driven by renewed analyst confidence in robust AI server CPU demand and strategic leadership additions sparking major partnership speculation. While some in the community eye this as a significant buying opportunity, others remain wary of a 'dead cat bounce' following its post-earnings volatility.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending following news of Apollo Global Management's $3.4 billion loan for xAI to acquire its chips, reinforcing the massive, multi-year AI infrastructure buildout that has the community highly anticipating upcoming earnings amidst strong bullish sentiment.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending after pulling its compounded semaglutide pill amid a patent infringement lawsuit from Novo Nordisk and intense FDA scrutiny, sparking a contentious debate among investors; while bears warn of significant legal and regulatory risks, bulls are aggressively buying the dip, banking on the company's core business, high short interest, and strong trading volume to fuel a potential short squeeze.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is trending ahead of its earnings report, with community discussion centered on expectations for strong results due to its critical role in AI infrastructure, amidst broader software sector re-evaluation and recent price volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026

Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026 Nektar...

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN FRANCISCO, Jan...

Where Nektar Therapeutics Stands With Analysts

Nektar Therapeutics (NASDAQ:NKTR) Earns "Buy" Rating from BTIG Research

BTIG Research reaffirmed a "buy" rating and issued a $118.00 target price on shares of Nektar Therapeutics in a research note on Thursday...

Nektar Therapeutics (NASDAQ:NKTR) Trading 7% Higher - Here's Why

Nektar Therapeutics (NASDAQ:NKTR) Stock Price Up 7% - Here's Why...

Insider Selling: Nektar Therapeutics (NASDAQ:NKTR) Insider Sells 3,867 Shares of Stock

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) insider Jonathan Zalevsky sold 3,867 shares of the business's stock in a transaction on Tuesday, January 20th. The shares were sold at an average...

Emerald Mutual Fund Advisers Trust Invests $13.27 Million in Nektar Therapeutics $NKTR

Emerald Mutual Fund Advisers Trust acquired a new stake in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) during the third quarter, according to its most recent 13F filing with the...

Nektar Therapeutics (NASDAQ:NKTR) Insider Sells $137,935.89 in Stock

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) insider Jonathan Zalevsky sold 3,867 shares of the company's stock in a transaction dated Tuesday, January 20th. The stock was sold at an average...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar...

Emerald Advisers LLC Takes Position in Nektar Therapeutics $NKTR

Emerald Advisers LLC bought a new stake in Nektar Therapeutics (NASDAQ:NKTR - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The...

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

NKTR
Nektar Therapeutics

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NKTR News

NKTRNektar Therapeutics